@misc{10481/94894,
year = {2023},
month = {5},
url = {https://hdl.handle.net/10481/94894},
abstract = {Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving
the clinical evolution of patients admitted to the Intensive Care Unit (ICU). This study aimed to
investigate the clinical and biochemical effects of administering NAC to critically ill patients with
COVID-19. A randomized controlled clinical trial was conducted on ICU patients (n = 140) with
COVID-19 and divided into two groups: patients treated with NAC (NAC-treated group) and patients
without NAC treatment (control group). NAC was administered as a continuous infusion with a
loading dose and a maintenance dose during the study period (from admission until the third day of
ICU stay). NAC-treated patients showed higher PaO2/FiO2 (p ≤ 0.014) after 3 days in ICU than their
control group counterparts. Moreover, C-reactive protein (p ≤ 0.001), D-dimer (p ≤ 0.042), and lactate
dehydrogenase (p ≤ 0.001) levels decreased on the third day in NAC-treated patients. Glutathione
concentrations decreased in both NAC-treated (p ≤ 0.004) and control (p ≤ 0.047) groups after 3 days
in ICU; whereas glutathione peroxidase did not change during the ICU stay. The administration of
NAC manages to improve the clinical and analytical response of seriously ill patients with COVID-19
compared to the control group. NAC is able to stop the decrease in glutathione concentrations.},
organization = {Project FIS PI10/1993 from the Spanish Carlos III Health
Institute},
organization = {European Regional Development Fund (ERDF) “a way of making Europe” funded via
the Consejería de Universidad, Investigación e Innovación de la Junta de Andalucía [REF. A-CTS-708-UGR20]},
organization = {FPU fellowship from the Spanish Ministry of Education (REF. FPU18/03702, REF. FPU18/03655)},
publisher = {MDPI},
keywords = {COVID-19},
keywords = {N-acetylcysteine},
keywords = {Mortality},
title = {Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19},
doi = {10.3390/nu15092235},
author = {Gamarra Morales, Yenifer and Herrera Quintana, Lourdes María and Molina-López, Jorge and Vázquez Lorente, Héctor and Machado Casas, Juan Francisco and Castaño Pérez, José and Pérez Villares, José Miguel and Planells Del Pozo, Elena María},
}